GSA Capital Partners LLP reduced its stake in LivaNova PLC (NASDAQ:LIVN) by 37.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,100 shares of the company’s stock after selling 6,053 shares during the quarter. GSA Capital Partners LLP’s holdings in LivaNova were worth $708,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. increased its stake in LivaNova by 79.3% in the 2nd quarter. BlackRock Inc. now owns 4,648,780 shares of the company’s stock worth $284,552,000 after buying an additional 2,055,891 shares in the last quarter. Koch Industries Inc. purchased a new stake in LivaNova in the 2nd quarter worth $1,384,000. State Street Corp increased its stake in LivaNova by 74.8% in the 2nd quarter. State Street Corp now owns 1,835,428 shares of the company’s stock worth $112,345,000 after buying an additional 785,268 shares in the last quarter. HealthCor Management L.P. purchased a new stake in LivaNova in the 2nd quarter worth $24,484,000. Finally, Dimensional Fund Advisors LP increased its stake in LivaNova by 42.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,317,901 shares of the company’s stock worth $92,331,000 after buying an additional 395,672 shares in the last quarter. 86.00% of the stock is currently owned by institutional investors.
A number of brokerages have issued reports on LIVN. Zacks Investment Research lowered LivaNova from a “buy” rating to a “hold” rating in a research note on Thursday, December 21st. ValuEngine lowered LivaNova from a “buy” rating to a “hold” rating in a research note on Wednesday, December 20th. BidaskClub lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 12th. Canaccord Genuity reiterated a “hold” rating and issued a $76.00 price target on shares of LivaNova in a research note on Tuesday, December 5th. Finally, Needham & Company LLC increased their price target on LivaNova from $93.00 to $97.00 and gave the stock a “buy” rating in a research note on Tuesday, December 5th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company’s stock. LivaNova has a consensus rating of “Hold” and a consensus price target of $79.71.
In related news, Director Alfred J. Novak sold 2,000 shares of LivaNova stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $85.77, for a total value of $171,540.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $81.39, for a total value of $81,390.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,830 shares of company stock valued at $569,350. Company insiders own 0.28% of the company’s stock.
LivaNova PLC (NASDAQ LIVN) opened at $82.28 on Friday. The firm has a market capitalization of $3,968.29, a PE ratio of 70.33, a PEG ratio of 2.27 and a beta of 0.61. The company has a current ratio of 2.03, a quick ratio of 1.42 and a debt-to-equity ratio of 0.04. LivaNova PLC has a 12-month low of $45.67 and a 12-month high of $88.56.
LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Thursday, November 2nd. The company reported $0.93 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.76 by $0.17. The firm had revenue of $309.70 million during the quarter, compared to analyst estimates of $301.22 million. LivaNova had a return on equity of 9.33% and a net margin of 4.63%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.78 earnings per share. sell-side analysts forecast that LivaNova PLC will post 3.24 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “GSA Capital Partners LLP Sells 6,053 Shares of LivaNova PLC (LIVN)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/14/gsa-capital-partners-llp-has-708000-stake-in-livanova-plc-livn.html.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.